Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).

Type of Cancer
Solid Tumor

Site
Bethesda

Protocol Number
GIST (Gastrointestinal Stromal Tumors) BLU-285

To Learn More Call
(201)-510-0950